In a move that could reshape the landscape of preclinical drug development, the Food and Drug Administration (FDA) recently announced a plan to phase out its requirement for use of animal models in evaluating monoclonal antibodies (mAbs) and other drug candidates.
Retinitis pigmentosa (RP) and retinal dystrophy are debilitating genetic disorders that lead to progressive vision loss due to the degeneration of photoreceptor cells in the retina. Despite advances in genetic research, effective treatments remain limited, making the development of innovative research models crucial. Organoids and Mesh MEA (microelectrode array, also referred to as multielectrode array) technology from Multi Channel Systems have emerged as powerful tools in studying these diseases, providing insights into retinal function and potential therapeutic approaches.
Unlike traditional MEA recordings that can only measure field potentials, the IntraCell uses a laser to precisely optoporate cardiomyocytes underneath each electrode.
